Visão geral da empresa
A biopharmaceutical entity operating primarily in Denmark and North America, Damora Therapeutics, Inc. focuses on developing therapies specifically designed to treat hematologic disorders. The company operates within the Healthcare sector and the Biotechnology industry, a classification that implies a high reliance on research and development expenditures before products can generate commercial revenue. Damora Therapeutics maintains a market capitalization of $1.54B while employing a workforce of just 7 individuals, indicating a capital-intensive business model with a very lean operational structure. Despite possessing a substantial market capitalization of $1.54B, the company reports N/A for annual revenue, which suggests that its valuation is driven largely by asset backing or future potential rather than current cash generation from sales. This disparity between a large market cap and lack of reported revenue highlights that the company's current position is heavily dependent on the successful execution of its lead product, DMR-001, an investigational monoclonal antibody therapy targeting CALR mutations, rather than established commercial earnings.
Saúde financeira
Damora Therapeutics reports a Net Income of $-209,839,000 over the trailing twelve months, while Revenue and EBITDA are listed as N/A or negative in the provided metrics, revealing a cost structure where operational expenses significantly outweigh any current income generation. The company generated Free Cash Flow of $-3,049,250, indicating a continuous burn rate that consumes the company's liquidity reserves without the benefit of current sales revenue to offset these outflows. All three profit margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company is not yet profitable and is currently operating at a loss across all levels of profitability analysis. The balance sheet shows a Cash position of $257.62M against a minimal Debt level of $68,000, resulting in a Debt to Equity ratio of 0.03, which signifies an extremely conservative balance sheet with negligible leverage. This liquidity is further supported by a Current Ratio of 12.98, a figure that indicates the company possesses more than twelve times the current assets necessary to cover its short-term liabilities, providing a robust buffer against immediate financial obligations. However, the Return on Equity stands at -163.8% and the Return on Assets is -16.5%, metrics that reveal that management has yet to generate positive returns on the capital invested in the company, reflecting the early-stage nature of the biotechnology development process.
Avaliação de valorização
The Trailing P/E and Forward P/E are both listed as N/A, implying that traditional earnings-based valuation methods are not applicable due to the company's lack of positive or substantial earnings, and thus no earnings trajectory can be inferred from these specific ratios. The Price to Book ratio is reported at -0.23, a negative figure that indicates the market capitalization is currently valued below the company's book value, often seen in biotech firms with significant intangible assets or liabilities that are not fully captured in standard equity valuations. Alternative valuation metrics such as Price to Sales are listed as N/A, while the EV/EBITDA stands at -46.59, suggesting that the valuation is heavily influenced by the negative earnings generation typical of pre-revenue or pre-profitability life sciences companies. The stock has demonstrated significant volatility, trading between a 52-Week High of $38.33 and a 52-Week Low of $2.01, placing the current trading price in a wide range that reflects high investor sentiment swings typical of speculative biotechnology assets. The Beta value of 1.60 indicates that the stock price is expected to be 60% more volatile than the broader market, exposing investors to higher risk fluctuations relative to a standard market index.
Growth & Income
The Revenue Growth and Earnings Growth rates are both listed as N/A, which prevents a direct comparison of whether earnings are growing faster or slower than revenue, as the company has not yet established a consistent pattern of commercial sales or profitable earnings growth. As a non-dividend payer, Damora Therapeutics reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that the company reinvests all available capital and retained earnings back into research and development activities rather than distributing income to shareholders. This reinvestment strategy is characteristic of biotechnology firms that prioritize product development and clinical trial progression over providing immediate income streams to investors. Consequently, the overall growth and income profile of Damora Therapeutics is defined by a reliance on future commercialization milestones rather than current revenue expansion or dividend distributions.